| 書目名稱 | Personalized Medicine as Innovation |
| 副標(biāo)題 | What Can Germany Lea |
| 編輯 | Katharina Kichko |
| 視頻video | http://file.papertrans.cn/745/744512/744512.mp4 |
| 概述 | Publication in the field of economic sciences.Includes supplementary material: |
| 叢書名稱 | Gesundheitsmanagement und Gesundheits?konomik |
| 圖書封面 |  |
| 描述 | Katharina Kichko supports the first Personalized Medicine learnings as she provides an approach overview in general as well as reimbursement and regulatory policies in particular. In focus stays analysis of the current Personalized Medicine in the U.S. and Germany as well as its preconditions for a wider implementation in the medical practice. Results have shown that the U.S. – as early knower – have the most projects as well as personalized drugs and therapies, while Germany – as a follower – has a significant number of projects and personalized products and more to come in future. |
| 出版日期 | Book 2019 |
| 關(guān)鍵詞 | Personalized Medicine; Individualized Medicine; medical trends; personalized drug; pharmacogenetic test; |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-3-658-27843-4 |
| isbn_softcover | 978-3-658-27842-7 |
| isbn_ebook | 978-3-658-27843-4Series ISSN 2523-7667 Series E-ISSN 2523-7675 |
| issn_series | 2523-7667 |
| copyright | Springer Fachmedien Wiesbaden GmbH, part of Springer Nature 2019 |
|Archiver|手機(jī)版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-10 18:53
發(fā)表于 2025-3-21 19:02:15
